XTX Topco Ltd Buys New Holdings in Immatics N.V. (NASDAQ:IMTX)

XTX Topco Ltd purchased a new stake in shares of Immatics N.V. (NASDAQ:IMTX - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 126,957 shares of the company's stock, valued at approximately $573,000. XTX Topco Ltd owned about 0.10% of Immatics as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in IMTX. Bank of America Corp DE grew its stake in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after purchasing an additional 2,231 shares during the period. Virtus ETF Advisers LLC boosted its holdings in shares of Immatics by 34.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after buying an additional 2,479 shares during the last quarter. Guggenheim Capital LLC bought a new stake in Immatics during the fourth quarter valued at approximately $101,000. Intellectus Partners LLC bought a new stake in Immatics during the first quarter valued at approximately $70,000. Finally, Forefront Analytics LLC increased its holdings in Immatics by 42.3% during the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock valued at $113,000 after buying an additional 4,731 shares during the last quarter. Hedge funds and other institutional investors own 64.41% of the company's stock.

Immatics Trading Down 0.3%

NASDAQ IMTX traded down $0.02 on Thursday, reaching $6.32. 329,857 shares of the stock were exchanged, compared to its average volume of 379,262. Immatics N.V. has a one year low of $3.30 and a one year high of $13.09. The firm has a market capitalization of $768.20 million, a PE ratio of -37.17 and a beta of 0.93. The company's 50-day simple moving average is $5.99 and its two-hundred day simple moving average is $5.17.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 14.73% and a negative return on equity of 4.52%. The firm had revenue of $20.12 million for the quarter, compared to the consensus estimate of $14.92 million. Sell-side analysts forecast that Immatics N.V. will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IMTX has been the topic of several analyst reports. Wall Street Zen cut shares of Immatics from a "hold" rating to a "strong sell" rating in a research note on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft began coverage on Immatics in a report on Wednesday, May 28th. They issued a "buy" rating and a $10.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $14.67.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.